Cargando…

Somatostatin Receptor-Directed PET/CT for Therapeutic Decision-Making and Disease Control in Patients Affected With Small Cell Lung Cancer

Somatostatin receptor (SSTR)–targeted PET/CT is used for patients affected with small cell lung cancer (SCLC), but the clinical impact has not been elucidated yet. We aimed to determine whether SSTR PET/CT can trigger relevant therapeutic management changes in patients with SCLC and whether those mo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Serfling, Sebastian E., Hartrampf, Philipp E., Zhi, Yingjun, Higuchi, Takahiro, Kosmala, Aleksander, Serfling, Julia, Schirbel, Andreas, Hörning, Anna, Buck, Andreas K., Weich, Alexander, Werner, Rudolf A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9988212/ https://www.ncbi.nlm.nih.gov/pubmed/36754127 http://dx.doi.org/10.1097/RLU.0000000000004591

Ejemplares similares

Impact of (68)Ga-FAPI-04 PET/CT on Staging and Therapeutic Management in Patients With Digestive System Tumors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Molecular imaging of arterial fibroblast activation protein: association with calcified plaque burden and cardiovascular risk factors
por: Kosmala, Aleksander, et al.
Publicado: (2023)

Somatostatin Receptor–Directed PET/CT Can Differentiate Between Different Subtypes of Head and Neck Paragangliomas
por: Zhi, Yingjun, et al.
Publicado: (2023)

Impact of Tumor Burden on Normal Organ Distribution in Patients Imaged with CXCR4-Targeted [(68)Ga]Ga-PentixaFor PET/CT
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Associations between Normal Organs and Tumor Burden in Patients Imaged with Fibroblast Activation Protein Inhibitor-Directed Positron Emission Tomography
por: Kosmala, Aleksander, et al.
Publicado: (2022)

Somatostatin receptor-directed molecular imaging for therapeutic decision-making in patients with medullary thyroid carcinoma
por: Serfling, Sebastian E., et al.
Publicado: (2022)

CXCR4-targeted molecular imaging after severe SARS-Cov-2 infection
por: Lambertini, Alessandro, et al.
Publicado: (2022)

Pitfalls in PSMA-PET/CT: intensive bone marrow uptake in a case with polycythemia vera
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Interobserver Agreement Rates on C-X-C Motif Chemokine Receptor 4–Directed Molecular Imaging and Therapy
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

Lymphoma-Sink Effect in Marginal Zone Lymphoma Based on CXCR4-Targeted Molecular Imaging
por: Kosmala, Aleksander, et al.
Publicado: (2023)

CXCR4-Directed PET/CT in Patients with Newly Diagnosed Neuroendocrine Carcinomas
por: Weich, Alexander, et al.
Publicado: (2021)

Training on Reporting and Data System (RADS) for Somatostatin-Receptor Targeted Molecular Imaging Can Reduce the Test Anxiety of Inexperienced Readers
por: Weich, Alexander, et al.
Publicado: (2022)

Interobserver Agreement Rates on Fibroblast Activation Protein Inhibitor–Directed Molecular Imaging and Therapy
por: Serfling, Sebastian E., et al.
Publicado: (2022)

Baseline clinical characteristics predict overall survival in patients undergoing radioligand therapy with [(177)Lu]Lu-PSMA I&T during long-term follow-up
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

mCRPC patients with PSA fluctuations under radioligand therapy have comparable survival benefits relative to patients with sustained PSA decrease
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

High Interobserver Agreement on PSMA PET/CT Even in the Absence of Clinical Data
por: Bundschuh, Ralph A., et al.
Publicado: (2023)

In-Vivo Somatostatin-Receptor Expression in Small Cell Lung Cancer as a Prognostic Image Biomarker and Therapeutic Target
por: Şen, Feyza, et al.
Publicado: (2023)

Changing Threshold-Based Segmentation Has No Relevant Impact on Semi-Quantification in the Context of Structured Reporting for PSMA-PET/CT
por: Mihatsch, Patrick W., et al.
Publicado: (2022)

Improved cancer detection in Waldeyer’s tonsillar ring by (68)Ga-FAPI PET/CT imaging
por: Serfling, S., et al.
Publicado: (2020)

Hematotoxicity and Nephrotoxicity in Prostate Cancer Patients Undergoing Radioligand Therapy with [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Whole-Body [(18)F]FDG PET/CT Can Alter Diagnosis in Patients with Suspected Rheumatic Disease
por: Fröhlich, Matthias, et al.
Publicado: (2021)

Targeting fibroblast activation protein in newly diagnosed squamous cell carcinoma of the oral cavity – initial experience and comparison to [(18)F]FDG PET/CT and MRI
por: Linz, Christian, et al.
Publicado: (2021)

CXCR4-targeted theranostics in oncology
por: Buck, Andreas K., et al.
Publicado: (2022)

SUV(mean) on baseline [(18)F]PSMA-1007 PET and clinical parameters are associated with survival in prostate cancer patients scheduled for [(177)Lu]Lu-PSMA I&T
por: Hartrampf, Philipp E., et al.
Publicado: (2023)

Development of Discordant Hypermetabolic Prostate Cancer Lesions in the Course of [(177)Lu]PSMA Radioligand Therapy and Their Possible Influence on Patient Outcome
por: Hartrampf, Philipp E., et al.
Publicado: (2021)

Somatostatin receptor based PET/CT in patients with the suspicion of cardiac sarcoidosis: an initial comparison to cardiac MRI
por: Lapa, Constantin, et al.
Publicado: (2016)

Metabolic Tumour Volume from PSMA PET/CT Scans of Prostate Cancer Patients during Chemotherapy—Do Different Software Solutions Deliver Comparable Results?
por: Hartrampf, Philipp E., et al.
Publicado: (2020)

Intraindividual comparison of [(177)Lu]Lu-DOTA-EB-TATE and [(177)Lu]Lu-DOTA-TOC
por: Hänscheid, Heribert, et al.
Publicado: (2021)

Therapeutic Effects of Lipid Lowering Medications on Myocardial Blood Flow, Inflammation, and Sympathetic Nerve Activity Using Nuclear Techniques
por: Higuchi, Takahiro, et al.
Publicado: (2022)

Theranostics in Hematooncology
por: Buck, Andreas K., et al.
Publicado: (2023)

Matched-pair analysis of [(177)Lu]Lu-PSMA I&T and [(177)Lu]Lu-PSMA-617 in patients with metastatic castration-resistant prostate cancer
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Prognostic implications of dual tracer PET/CT: PSMA ligand and [(18)F]FDG PET/CT in patients undergoing [(177)Lu]PSMA radioligand therapy
por: Michalski, Kerstin, et al.
Publicado: (2020)

Successful combination of selpercatinib and radioiodine after pretherapeutic dose estimation in RET-altered thyroid carcinoma
por: Werner, Rudolf A., et al.
Publicado: (2022)

Predicting Microenvironment in CXCR4- and FAP-Positive Solid Tumors—A Pan-Cancer Machine Learning Workflow for Theranostic Target Structures
por: Marquardt, André, et al.
Publicado: (2023)

Somatostatin receptor expression in small cell lung cancer as a prognostic marker and a target for peptide receptor radionuclide therapy
por: Lapa, Constantin, et al.
Publicado: (2016)

Reduced Segmentation of Lesions Is Comparable to Whole-Body Segmentation for Response Assessment by PSMA PET/CT: Initial Experience with the Keyhole Approach
por: Hartrampf, Philipp E., et al.
Publicado: (2022)

Somatostatin receptor PET/CT in restaging of typical and atypical lung carcinoids
por: Prasad, Vikas, et al.
Publicado: (2015)

Somatostatin receptor expression in Merkel cell carcinoma as target for molecular imaging
por: Buder, Kristina, et al.
Publicado: (2014)

Early biochemical and radiographic response after one cycle of [(177)Lu]Lu-PSMA I&T radioligand therapy in metastatic castration-resistant prostate cancer patients
por: Cytawa, Wojciech, et al.
Publicado: (2023)

Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
por: Werner, Rudolf A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_toebuvou2b5t9g48jq8jnma2t1